ENDRA Life Sciences Inc.'s intellectual property portfolio has reached an 80-patent milestone, thanks to the recent awarding of five new patents—three in Europe and two in China—for its TAEUS system thermoacoustic technology.

恩德拉生命科学公司（ENDRA Life Sciences Inc.）的知识产权组合已达到80项专利的里程碑，这归功于其TAEUS系统热声技术最近授予了五项新专利，其中三项在欧洲，两项在中国。

'With the issuance of these five patents, we've reached a significant milestone of 80 global patents,' ENDRA Chairman/CEO Francois Michelon said. 'Our IP portfolio safeguards and sets apart ENDRA’s thermoacoustic technology in areas of high unmet clinical need. We're actively enhancing our intellectual property to secure our technology in key global markets and exploring licensing opportunities for indications beyond our core focus, opening further growth avenues for the company.'.

ENDRA董事长兼首席执行官弗朗索瓦·米歇伦（FrancoisMichelon）说，随着这五项专利的发布，我们已经达到了80项全球专利的重要里程碑我们的知识产权产品组合保障并将ENDRA的热声技术用于高度未满足临床需求的领域。我们正在积极增强我们的知识产权，以确保我们的技术在关键的全球市场上的安全，并探索超出我们核心重点的适应症的许可机会，为公司开辟进一步的增长途径。”。

The following five patents were issued:

发布了以下五项专利：

European Patent No. EP4051151: “Radio Frequency Applicator and Thermoacoustic Imaging System Employing the Same,” covers a radio frequency (RF) applicator device and system for providing reliable RF energy to a target area of tissue. Specifically, this patent structurally defines ENDRA's solution to providing RF energy to targeted tissue regions for applications, such as liver fat quantification..

欧洲专利号EP4051151：“射频施加器和使用该射频施加器的热声成像系统”涵盖了一种射频（RF）施加器装置和系统，用于向组织的目标区域提供可靠的RF能量。具体而言，该专利在结构上定义了ENDRA的解决方案，该解决方案可为应用的目标组织区域提供射频能量，例如肝脏脂肪定量。。

European Patent No. EP4037554: “Method and System for Determining a Material Type of an Object of Interest,” protects ENDRA's method and system for determining a material type by utilizing TAEUS. The patent has potential application beyond liver measurements, which may include outside the human body..

欧洲专利号EP4037554：“确定感兴趣物体材料类型的方法和系统”，保护ENDRA利用TAEUS确定材料类型的方法和系统。该专利的潜在应用范围超出了肝脏测量，可能包括人体外。。

European Patent No. EP4037551: “Method and System for Determining a Parameter of a Material of Interest,” relates to a novel method for determining at least one parameter of interest of a material utilizing TAEUS. Examples of potential parameters of interest include the Grüneisen parameter, which is the ratio of thermal pressure to thermal energy and conductivity.

欧洲专利号EP4037551：“确定感兴趣材料参数的方法和系统”涉及一种利用TAEUS确定材料至少一个感兴趣参数的新方法。感兴趣的潜在参数的例子包括Grüneisen参数，它是热压与热能和电导率的比率。

In addition, this patent expands the imaging potential for the TAEUS technology outside the human body for select applications, such as material testing and identification..

此外，该专利扩大了TAEUS技术在人体外的成像潜力，可用于某些应用，例如材料测试和识别。。

Chinese Patents ZL2019800868227 and ZL202110813939X: “Method and System for Monitoring Tissue Temperature,” both patents relate to novel methods and systems for monitoring tissue temperature with TAEUS during surgical procedures such as thermotherapy and cryotherapy.

中国专利ZL2019800868227和ZL202110813939X：“监测组织温度的方法和系统”，这两项专利都涉及在热疗和冷冻治疗等外科手术过程中使用TAEUS监测组织温度的新方法和系统。

ENDRA Life Sciences' Thermo Acoustic Enhanced UltraSound (TAEUS) technology characterizes tissue like MRI, but at 1/40th the cost and at the point of patient care. TAEUS is designed to work in concert with more than 700,000 ultrasound systems currently in use globally. TAEUS is initially focused on the measuring liver fat to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects more than 2 billion people globally, and for which there are no practical diagnostic tools.

ENDRA Life Sciences的热声增强超声（TAEUS）技术表征了类似组织的MRI，但在成本和患者护理方面的成本是其的1/40。TAEUS旨在与目前全球使用的70多万个超声波系统协同工作。TAEUS最初专注于测量肝脏脂肪以评估和监测脂肪变性肝病（SLD）（以前称为NAFLD-NASH），这是一种影响全球20多亿人的慢性肝病谱，目前尚无实用的诊断工具。

Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including tissue temperature imaging during energy-based surgical procedures..

除了肝脏之外，ENDRA正在探索TAEUS的其他几种临床应用，包括基于能量的外科手术过程中的组织温度成像。。

ENDRA Life Sciences is based in Ann Arbor, Mich., and has offices/facilities in England, France, Germany, and The Netherlands.

恩德拉生命科学公司总部位于密歇根州安阿伯，在英国、法国、德国和荷兰设有办事处/设施。